MARKET

GRI

GRI

GRI Bio
NASDAQ
2.030
-0.120
-5.58%
After Hours: 2.040 +0.01 +0.49% 18:56 05/15 EDT
OPEN
2.140
PREV CLOSE
2.150
HIGH
2.157
LOW
2.030
VOLUME
22.25K
TURNOVER
--
52 WEEK HIGH
80.36
52 WEEK LOW
2.030
MARKET CAP
3.59M
P/E (TTM)
-0.0167
1D
5D
1M
3M
1Y
5Y
1D
GRI Bio reports Q1 results
Seeking Alpha · 1d ago
GRI Bio Highlights Promising Phase 2a IPF Data, Outlook
TipRanks · 2d ago
GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate
Benzinga · 2d ago
GRI Bio Q1 net loss narrows on lower R&D expenses
Reuters · 2d ago
GRI BIO Q1 NET INCOME USD -2 MILLION
Reuters · 2d ago
Analysts’ Top Healthcare Picks: GRI Bio (GRI), Ovid Therapeutics (OVID)
TipRanks · 2d ago
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Barchart · 2d ago
Gri Bio Q1 FY26 net loss narrows to $2 million from year-ago quarter
PUBT · 2d ago
More
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).

Webull offers GRI Bio Inc stock information, including NASDAQ: GRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRI stock methods without spending real money on the virtual paper trading platform.